Last reviewed · How we verify

An Open-Label Study to Evaluate the Single Dose Pharmacokinetic Profile and Safety of OROS® Hydromorphone in Chinese Subjects With Cancer Who Are Not Opioid Tolerant

NCT01824524 Phase 1 COMPLETED

The purpose of this study is to assess the single dose pharmacokinetic profile (explores what a drug does to the body) and safety of Osmotic Release Oral System (OROS) hydromorphone in chinese participants with cancer (abnormal tissue that grows and spreads in the body) who are not opioid (morphine-like medications) tolerant (decrease in response to a fixed dosage of drug over time and higher doses of a drug are needed to get desired effect).

Details

Lead sponsorXian-Janssen Pharmaceutical Ltd.
PhasePhase 1
StatusCOMPLETED
Enrolment12
Start date2011-12
Completion2012-08

Conditions

Interventions

Primary outcomes

Countries

China